First Patient Dosed in Neuraly’s NLY01 Trial Testing Safety, Efficacy
The first patient has been dosed in a Phase 2 study testing NLY01, an investigational compound with a new mechanism of action designed to stall the progression of Parkinson’s disease. NLY01, being developed by Neuraly, could prevent nerve cell loss in the brain by stopping the toxic activation of immune cells. Read more >>